Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
Details
The content you want to view is only available to Zendy Plus users.Already have an account? Click here. to sign in.